Rallybio Corporation

About Rallybio Corporation

Rallybio is dedicated to developing transformative therapies for patients with rare diseases. Their mission is to tackle challenging and inaccessible medical needs, aiming to profoundly change outcomes for these patients rather than making incremental progress.

Products & Services

RLYB116:A C5 inhibitor with potential to be best-in-class for patients with complement-mediated diseases, currently in a confirmatory PK/PD study.

RLYB332:A product in Rallybio's pipeline focused on addressing rare diseases (specific details not provided in content).

Specialties

Rare Diseases Complement Dysregulation Hematology Metabolic Diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Equity Milestone T: - FT: Equity Milestone	A: 12500000 MR: - FA: 12.5 million FAN: 12500000	D: 2025-09-03 FD: 2025-09-03	1 investors

Equity Milestone Latest

2025-09-03

$12.5M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Rachael Alford

Vice President of Global Process Development

S

Sharon Arrol

Director, Bioanalytical Development, R&D

M

Michael Bombara

Executive Director of Clinical Business Operations

D

Danielle Camputaro

People & Culture Partner

L

Laura A. Ekas

M

Melissa Haskell

DVM, DABT

View 25 more team members with Pro

Unlock Full Team Directory

Recent News